“Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?”

已完结 10 由朱泽均发布于 2026/7/1 22:35:15

DOI:10.1016/j.ejca.2026.116796
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/j.ejca.2026.116796

Elsevier

Abstract：The therapeutic landscape for HER2-positive breast cancer (BC) is evolving rapidly with the advent of antibody–drug conjugates such as trastuzumab deruxtecan (T-DXd). Recently, positive resu

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerDevelopment of whey-protein–pullulan films loaded with Saussurea Costus latex phenolics as active packaging liners for shelf-life extension and gray-mold suppression in post-harvest cherry tomatoes